Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 18, Issue 2, pp. 568-576
PubMed
Published By
Print ISSN
Online ISSN
History
- Received March 21, 2011
- Revision received November 1, 2011
- Accepted November 6, 2011
- Published first November 16, 2011.
Article Versions
- Previous version (November 16, 2011 - 08:42).
- You are viewing the most recent version of this article.
Copyright & Usage
©2011 American Association for Cancer Research.
Author Information
- Keith T. Flaherty1,
- Patricia M. LoRusso2,
- Angela DeMichele1,
- Vandana G. Abramson1,
- Rachel Courtney3,
- Sophia S. Randolph3,
- M. Naveed Shaik3,
- Keith D. Wilner3,
- Peter J. O'Dwyer1, and
- Gary K. Schwartz4
- Authors' Affiliations: 1Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania; 2Karmanos Cancer Institute, Detroit, Michigan; 3Pfizer Oncology, San Diego, California; and 4Memorial Sloan-Kettering Cancer Center, New York
- Corresponding Author:
Peter J. O'Dwyer, Abramson Cancer Center, University of Pennsylvania, 16 Penn Tower, 3400 Spruce St., Philadelphia, PA 19104. Phone: 215-662-7606; Fax: 215-349-8551; E-mail: peter.odwyer{at}uphs.upenn.edu
January 2012
Volume 18, Issue 2
Volume 18, Issue 2
Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
Jump to section
Advertisement